On December 3, 2021, in accordance with the relevant provisions of the Measures for the Administration of the Recognition of High and New Technology Enterprises, the Guidelines for the Administration of the Recognition of High and New Technology Enterprises, and the Implementation Measures for the Administration of the Recognition of High and New Technology Enterprises in Shanghai issued by the Ministry of Science and Technology, the Ministry of Finance, and the State Administration of Taxation, Shanghai Shende Green Medical Era Technology Co., Ltd. was recognized as the "fifth batch of high-tech enterprises in Shanghai" in 2021.
High and new technology enterprises belong to the strategic emerging industry supported by the state, so the selection and eligibility are very strict, which calls for continuous research and transformation of technological achievements, the core independent intellectual property rights, and high growth potential and high economic benefits. Obtaining this highly valuable qualification stands for another milestone in the development history of Shende Green Medical Era, which means that Shende's scientific and technological achievements, research and innovation capabilities, and technical strength have been highly recognized by the government, society, and industry.
According to relevant policies, Shende Green Medical Era can enjoy relevant preferential policies for the recognition of high-tech enterprises in Shanghai for three consecutive years since the year it passed the recognition of high-tech enterprise of Shanghai: tax relief, capital subsidies, talent settlement, land rent, and energy conservation and emission reduction support policies. The identification of high-tech enterprise and relevant tax incentives will exert a positive impact on the D-round financing of the company and the process of stock exchange listing next year.
Founded in May 2013, Shende Green Medical Era is an innovation and entrepreneurship team, with academician Chen Yazhu of Shanghai Jiaotong University(SJTU) as the general consultant, Professor Shen Guofeng as the founder, and nearly 20 doctors and masters from SJTU, endeavoring to carry out technical breakthroughs and product operation of the magnetic resonance-guided phased controlled high intensity focused ultrasound non-invasive treatment system, a 25-year major scientific and technological achievement of academician Chen Yazhu's team.
Shende Green Medical Era is continuously focusing on the research, development and production of domestic high-end precision non-invasive treatment equipment with fully independent intellectual property rights, which is used for non-invasive treatment of major diseases such as tumors and nervous system diseases, covering the entire industrial chain of high-end medical device industry manufacturing, commercial operation, and after-sales service. Shende Green Medical Era endeavors to drive national medical device brands with technological innovation, enter the international market, and build an international medical device strong enterprise, and is expected to become a new engine for domestic high-end ethnic precision non-invasive treatment devices.
The development of Shende Green Medical Era is in line with the national import substitution trend, matching a huge market of benign and malignant tumors, cardiovascular and cerebrovascular diseases and brain nervous system diseases. Currently, Shende Green Medical Era is making great efforts to solve the technical challenges of its six major products, drive the R&D and industrialization of more diversified products financed with German capital. The persistence and explosive power of the technological innovation platform has created strong growth momentum and potential.
Currently, Shende Green Medical Era treatment system for pain relief of advanced metastatic bone tumors has obtained EU CE certification, and three products for the four major indications including uterine fibroids/adenomyosis, pain relief for advanced metastatic bone tumors, and breast adenomas have entered the clinical trial stage. Three products targeting the five major indications of Parkinson's disease/essential tremor/glioma, prostate cancer, and thyroid cancer are expected to initiate human clinical trials in 2022.
Beyond that, comprehensive technical development and industrial layout have been carried out for other transcranial system diseases such as BBB, epilepsy, liver cancer, pancreatic cancer, prostate cancer, kidney cancer, abdominal malignancies, intractable hypertension, thrombolysis, atherosclerosis and other cardiovascular and cerebrovascular diseases.
Professor Shen Guofeng, the founder of Shende Green Medical Era, said: In the future, Shende Green Medical Era will continue its commitment to empowering high-tech production, strengthening core capabilities such as the operation of the "MRgPHIFU" technology innovation platform, intellectual property barriers, product fission, and commercial operation, erecting the "Chinese backbone" of the domestic high-end medical device industry, inheriting the spirit of the Red Revolution, and creating a national medical device brand!
EN